Business Context and Reporting Period
This Form 6-K filing by DBV Technologies S.A. covers the month of June 2018. The report serves as a notification regarding the convening of the Company's Ordinary and Extraordinary General Meeting scheduled for June 22, 2018. DBV Technologies is a biopharmaceutical company developing Viaskin, an epicutaneous immunotherapy (EPIT) platform for treating food allergies and other immune diseases.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural announcement regarding shareholder meetings and does not contain financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this filing. The document focuses on corporate governance procedures rather than operational or financial performance updates.
Guidance, Outlook, and Management Commentary
- General Meeting: The Ordinary and Extraordinary General Meeting will be held on June 22, 2018, at 8:30 a.m. CEST at the Company's headquarters in Montrouge, France.
- Documentation: Preparatory documents, including the agenda and draft resolutions, are available on the Company's website. The convening notice was published in the BALO and Legal Gazette on June 6, 2018.
- Shareholder Rights: Registered shareholders may request documents electronically until the fifth day prior to the meeting. Bearer shareholders must submit a certificate of participation to exercise this right.
- Business Outlook: The Company continues clinical trials for Viaskin Peanut and Viaskin Milk, preclinical development for Viaskin Egg, and a proof-of-concept study for Viaskin Milk in Eosinophilic Esophagitis.
Key Facts for Investor Verification
- Verify the date and location of the General Meeting: June 22, 2018, at 177-181 Avenue Pierre Brossolette, Montrouge, France.
- Confirm the availability of preparatory documents on the Company's Investor Relations website.
- Note the trading symbols: Euronext Paris (DBV) and Nasdaq Global Select Market (DBVT).
- Understand that this filing contains no financial results; investors should refer to Form 20-F or quarterly reports for financial data.